+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 84 Pages
  • May 2025
  • GlobalData
  • Amgen Inc.
  • ID: 1322529
Amgen Inc (AMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amgen Inc (Amgen) is a biotechnology company that focuses on discovering, developing, manufacturing, and delivering innovative medicines. The company's products focus on the therapy areas such as cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases. Amgen offers its products across pharmaceutical wholesale distributors and directly to consumer channels, including healthcare providers, including physicians, clinics, hospitals, and pharmacies, through brands Actimmune, Blincyto, Epogen, Kanjinti, Mvas, Parsabiv, and Tepezza, among others, in Asia Pacific, the Americas, Europe, the Middle East, and Africa. It operates manufacturing facilities in the US, Puerto Rico, Ireland, the Netherlands, and Singapore. Amgen is headquartered in Thousand Oaks, California, the US.

Amgen Inc Key Recent Developments

  • May 15, 2025: Regeneron Prevails Over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
  • Apr 28, 2025: Amgen to invest $900m in Ohio manufacturing facility
  • Feb 04, 2025: Amgen Announces Q4 and Full Year 2024 Results
  • Jan 27, 2025: Amgen opens new drug substance facility in North Carolina, US

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Amgen Inc - Key Facts
  • Amgen Inc - Key Employees
  • Amgen Inc - Key Employee Biographies
  • Amgen Inc - Major Products and Services
  • Amgen Inc - History
  • Amgen Inc - Company Statement
  • Amgen Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • Amgen Inc - Business Description
  • Geographical Segment: Rest of the world (ROW)
  • Performance
  • Geographical Segment: U.S.
  • Performance
  • R&D Overview
  • Amgen Inc - Corporate Strategy
  • Amgen Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Amgen Inc - Strengths
  • Amgen Inc - Weaknesses
  • Amgen Inc - Opportunities
  • Amgen Inc - Threats
  • Amgen Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Amgen Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 15, 2025: Regeneron Prevails Over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
  • Apr 28, 2025: Amgen to invest $900m in Ohio manufacturing facility
  • Feb 04, 2025: Amgen Announces Q4 and Full Year 2024 Results
  • Jan 27, 2025: Amgen opens new drug substance facility in North Carolina, US
  • Dec 06, 2024: Amgen Announces $1 Billion Manufacturing Expansion in North Carolina
  • Nov 20, 2024: Amgen Announces Appointment of Howard Chang as Senior Vice President of Research
  • Oct 31, 2024: Amgen earns higher revenues in Q3 2024, puts rare diseases in the spotlight
  • Sep 30, 2024: Family Heart Foundation Launches “Cholesterol Connect,” Free Screening and Personalized Support Program to Address the Leading Cause of Death in America
  • Sep 23, 2024: Amgen to Host Conference Call to Discuss New Topline Data in Inflammation and Rare Disease
  • Sep 18, 2024: Amgen Irish Open Swings Toward Sustainability with Event Broadcast Powered by Green Hydrogen
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Amgen Inc, Key Facts
  • Amgen Inc, Key Employees
  • Amgen Inc, Key Employee Biographies
  • Amgen Inc, Major Products and Services
  • Amgen Inc, History
  • Amgen Inc, Other Locations
  • Amgen Inc, Subsidiaries
  • Amgen Inc, Joint Venture
  • Amgen Inc, Key Competitors
  • Amgen Inc, Ratios based on current share price
  • Amgen Inc, Annual Ratios
  • Amgen Inc, Interim Ratios
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
  • Amgen Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Amgen Inc, Performance Chart (2020 - 2024)
  • Amgen Inc, Ratio Charts
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
  • Amgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Sandoz Group AG
  • Regeneron Pharmaceuticals Inc
  • Pfizer Inc
  • Novartis AG
  • Millennium Pharmaceuticals Inc
  • Merck & Co Inc
  • Johnson & Johnson Innovative Medicine
  • GSK plc
  • Genentech USA Inc
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Coherus BioSciences Inc
  • Celgene Corp
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • Asahi Kasei Pharma Corp
  • AbbVie Inc